Evidence map›Paper›PMID 40691732›Full record

ArticleAntonie van Leeuwenhoek2025

Antibacterial and anticancer activities of rhizobacterial lipopeptides against carcinogenic bacteria.

Nawal E Al-Hazmi

Abstract read
PubMed Publisher
In one paragraph

Article in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Screening and Genomic Analysis ofMicroorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nawal E Al-HazmiDepartment of Chemistry, Division of Biology (Microbiology), University College of Qunfudah, Umm Al-Qura University, Qunfudah, Saudi Arabia. nehazmi@uqu.edu.sa.ORCID http://orcid.org/0000-0002-3745-7456

Funding

Umm Al-Qura University 25UQU4281337GSSR02
6 · The paper itself

Abstract

Rhizosphere-derived lipopeptides, including surfactin, iturin, and fengycin from Bacillus spp., exhibit potent antibacterial and anticancer properties. This study evaluated the antibacterial activity, mechanism of action, anti-biofilm effects, and anticancer potential of these lipopeptides individually and in combination. The minimum inhibitory concentration (MIC) against pathogenic Gram-negative bacteria (Bacteroides fragilis, Escherichia coli, Fusobacterium nucleatum, Helicobacter pylori, Neisseria gonorrhoeae, Porphyromonas gingivalis, and Salmonella enterica) was determined using the broth dilution method. Among the single lipopeptides, fengycin demonstrated the strongest antibacterial effect, whereas the combination of all three lipopeptides exhibited the lowest MIC values, reducing bacterial growth by approximately 95% more than chloramphenicol. Mechanistically, lipopeptide treatments increased bacterial membrane permeability, with the three-lipopeptide mixture inducing 60% greater electrolyte leakage than chloramphenicol. Additionally, lipopeptides significantly reduced bacterial DNA content, with the three-lipopeptide combination leading to a 321% greater reduction than chloramphenicol. Biofilm formation was also markedly inhibited, particularly by fengycin and the lipopeptide mixtures. Furthermore, the anticancer activity of lipopeptides was assessed using the MTT assay against gastric, pancreatic, liver, colon, esophageal, and breast cancer cell lines. The three-lipopeptide mixture exhibited the highest cytotoxicity, with IC50 values approximately 82% lower than those of doxorubicin. These findings highlight the potential of rhizosphere lipopeptides as promising antibacterial and anticancer agents, warranting further investigation for therapeutic applications.

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsGram-Negative BacteriaLipopeptidesBiofilmsCell Line, TumorHumansMicrobial Sensitivity TestsRhizosphereAnti-Bacterial AgentsAntineoplastic AgentsLipopeptidesAntibacterialAnticancerBacillus spp.FengycinIturinSurfactin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.